(CNN) The controversial new drug for Alzheimer's disease, Aduhelm, is priced at $56,000 a year for treatment -- but Alzheimer's patients won't be the only ones shouldering the cost. Here's how it's expected to work: Because Aduhelm will be administered in physicians' offices, it should be covered under Medicare Part B, not Part D plans, which pay for medications bought at pharmacies. For new Part B drugs, Medicare typically reimburses 103% of the list price. Total Medicare spending for all Part B drugs was $37 billion in 2019. If a million patients receive the drug, total spending would top $57 billion, Kaiser said.

Source: CNN July 10, 2021 14:03 UTC